阿伐可泮治疗65岁及以上ANCA相关血管炎患者的疗效与安全性:ADVOCATE试验的事后分析
ADVOCATE试验事后分析纳入160例≥65岁肉芽肿性多血管炎(GPA)或显微镜下多血管炎(MPA)患者,比较阿伐可泮方案与泼尼松递减方案。第26周缓解率两组相近,第52周持续缓解率阿伐可泮组数值较高,复发率较低,糖皮质激素剂量分别降低61%(65-74岁)和49%(≥75岁),不良事件比例组间相似。
要点
- ≥65岁GPA或MPA患者中,阿伐可泮方案第26周缓解率与泼尼松递减方案相近。
- 第52周持续缓解率阿伐可泮组数值较高,65-74岁为65.0% vs 55.1%,≥75岁为65.4% vs 56.0%。
- 阿伐可泮组平均糖皮质激素剂量分别降低61%(65-74岁)和49%(≥75岁),糖皮质激素毒性更低。
核心结论
- 这些数据支持以阿伐可泮为基础的方案治疗≥65岁GPA或MPA患者的疗效和安全性。
研究设计与样本
- 为3期ADVOCATE试验的描述性事后分析,该试验比较阿伐可泮与泼尼松递减方案,并联合利妥昔单抗或环磷酰胺。
- 分析纳入160例年龄≥65岁的GPA或MPA患者,其中109例年龄65-74岁,51例年龄≥75岁。
主要发现
- 第26周缓解率:65-74岁亚组阿伐可泮组71.7% vs 泼尼松递减组69.4%;≥75岁亚组73.1% vs 72.0%。
- 第52周持续缓解率:65-74岁亚组阿伐可泮组65.0% vs 泼尼松递减组55.1%;≥75岁亚组65.4% vs 56.0%。
- 复发率:65-74岁亚组阿伐可泮组12.3% vs 泼尼松递减组18.8%;≥75岁亚组3.8% vs 20.8%。
- 两个治疗组均观察到估算肾小球滤过率和健康相关生活质量的改善。
- 与泼尼松递减方案相比,阿伐可泮组平均糖皮质激素剂量在65-74岁亚组降低61%、在≥75岁亚组降低49%,且糖皮质激素毒性更低;各年龄亚组内不良事件患者比例组间相似。
关键数值与推荐
- 第26周缓解率:65-74岁亚组阿伐可泮组71.7% vs 泼尼松递减组69.4%;≥75岁亚组73.1% vs 72.0%。
- 第52周持续缓解率:65-74岁亚组阿伐可泮组65.0% vs 泼尼松递减组55.1%;≥75岁亚组65.4% vs 56.0%。
- 复发率:65-74岁亚组阿伐可泮组12.3% vs 泼尼松递减组18.8%;≥75岁亚组3.8% vs 20.8%。
- 平均糖皮质激素剂量降低幅度:65-74岁亚组61%,≥75岁亚组49%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the efficacy and safety of avacopan in patients aged ≥65 years with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in the phase 3 ADVOCATE trial of avacopan vs a prednisone taper, plus either rituximab or cyclophosphamide. METHODS: In this descriptive, post hoc analysis, patients receiving avacopan or a prednisone taper were stratified by age. Key efficacy outcomes included the rate of remission at week 26 and sustained remission at week 52. RESULTS: Of 160 patients aged ≥65, 109 were aged 65-74 and 51 were ≥75. Remission at week 26 was achieved in 71.7% vs 69.4% of patients aged 65-74 and 73.1% vs 72.0% aged ≥75 in the avacopan vs prednisone taper groups, respectively. Sustained remission at week 52 was observed in 65.0% vs 55.1% of patients aged 65-74 and 65.4% vs 56.0% aged ≥75. Relapse rates in the avacopan vs prednisone taper groups were 12.3% vs 18.8% and 3.8% vs 20.8% in the 65-74 and ≥75 subgroups, respectively. Improvements in estimated glomerular filtration rate and health-related quality of life were observed in both treatment groups. Use of avacopan compared with a prednisone taper was associated with a 61% and 49% reduction in mean glucocorticoid dose in the 65-74 and ≥75 subgroups, respectively, and lower glucocorticoid toxicity. The proportions of patients with adverse events were similar between treatment groups within each age subgroup. CONCLUSION: These data support the efficacy and safety of an avacopan-based regimen to treat patients with GPA or MPA aged ≥65.
引用
- Geetha D, Pagnoux C, Sattui SE, et al. Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial. Rheumatology (Oxford). 2025. PMID: 40037556. doi:10.1093/rheumatology/keaf122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。